XML 54 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
shares in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2020
Mar. 31, 2020
Aug. 31, 2018
Mar. 31, 2021
Sep. 30, 2020
Mar. 31, 2020
Dec. 31, 2018
Dec. 31, 2020
Dec. 31, 2019
Other Commitments [Line Items]                  
Obligation expiration year       2021          
Gain (loss) on strategic investment       $ 145,000   $ (1,497,000)      
Restricted cash   $ 5,770,000   5,770,000   5,770,000   $ 5,770,000 $ 4,787,000
Letter of Credit | Corporate Credit Card Program                  
Other Commitments [Line Items]                  
Restricted cash       2,000,000.0          
Letter of Credit | Fleet Program                  
Other Commitments [Line Items]                  
Restricted cash       400,000          
Cersci Therapeutics                  
Other Commitments [Line Items]                  
Upfront consideration and transaction costs $ 52,800,000                
Upfront payment $ 44,300,000                
Upfront payment conditions The Company incurred an aggregate of $52.8 million in upfront consideration and transaction costs, of which, $44.3 million was paid through the issuance of approximately 1.2 million shares of the Company’s common stock.                
Common stock issuance 1.2                
Cersci Therapeutics | Research and development                  
Other Commitments [Line Items]                  
Assets acquisition and upfront payment         $ 45,700,000        
License Agreements                  
Other Commitments [Line Items]                  
Upfront payment       $ 0   10,000,000.0      
License Agreements | Neuren | North America                  
Other Commitments [Line Items]                  
Upfront payment   10,000,000.0              
Upfront license fee     $ 10,000,000.0            
License Agreements | Neuren | Research and development | North America                  
Other Commitments [Line Items]                  
Upfront payment           10,000,000.0 $ 10,000,000.0    
Maximum                  
Other Commitments [Line Items]                  
Percentage of royalty payments obligation on net product sales       2.00%          
Mile stone payments payable       $ 2,200,000,000          
Maximum | Cersci Therapeutics | Development Commercialization and Sales Milestones                  
Other Commitments [Line Items]                  
Compensation expense related to mergers to former holders $ 887,000,000.0                
Maximum | License Agreements | Neuren | North America                  
Other Commitments [Line Items]                  
Mile stone payments payable   $ 515,000,000.0 $ 455,000,000.0     $ 515,000,000.0